Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Short term Debt came in at $40.0 million in Q1 2026, down 38.46% YoY from $65.0 million in Q1 2025, and little changed on a QoQ basis from $40.0 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 3 years of Short term Debt data on file, last reported at $40.0 million in Q1 2026.
- Quarterly Short term Debt fell 38.46% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 38.46% YoY) and the FY2025 annual result came in at $40.0 million, changed N/A from the prior year.
- Short term Debt steadied at $40.0 million in Q1 2026, from $40.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $65.0 million in Q1 2025 to a low of $1.6 million in Q4 2024.
- A 3-year average of $37.8 million and a median of $40.0 million in 2025 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2025 — Short term Debt surged 2361.54% — and 2026, when it slumped 38.46%.
- Tracing ARWR's Short term Debt over 3 years: stood at $1.6 million in 2024, then surged by 2361.54% to $40.0 million in 2025, then changed by 0.0% to $40.0 million in 2026.
- The last three Short term Debt figures came in at $40.0 million (Q1 2026), $40.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Mar 31, 2026 | 40.00 Mn |
| Dec 31, 2025 | 40.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | 65.00 Mn |
| Dec 31, 2024 | 1.63 Mn |